Horizon Therapeutics Plc - Company Profile
Powered by 
All the data and insights you need on Horizon Therapeutics Plc in one report.
$295
- Save hours of research time and resources with
our up-to-date Horizon Therapeutics Plc Strategy Report
- Understand Horizon Therapeutics Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Horizon Therapeutics Plc Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Horizon Therapeutics Plc Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 18 Aug 2022 | Lorem |
| LoA Update: Horizon’s Raviciti has bleak advancement prospects in cystic fibrosis following Phase I/II trial termination | 28 Mar 2022 | William Newton |
| Horizon’s Phase III extension trial for teprotumumab accrues 35 patients from pivotal trial in thyroid eye disease, exec says | 21 Oct 2019 | Shuan Sim |
| Roche/Chugai’s satralizumab and Viela Bio’s inebilizumab unlikely to receive label inclusion for AQP4- patients in neuromyelitis optica spectrum disorder, experts say | 26 Sep 2019 | Shuan Sim |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward